As regards clinical trials, in phase I (Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies) and III trials (EXAM trial), CBZ showed an acceptable safety profile (Table 2 ), a longer progression-free survival (PFS) (11.2 months versus 4.0 months in the placebo arm, p < 0.001) and overall survival (OS) (26.6 versus 21.1 months, although the difference did not reach statistical significance, p = 0.24) [ 20 , 21 ].
← all excerpts
Cabozantinib for different endocrine tumours: killing two birds with one stone. A systematic review of the literature.
3
0.2400
0.2400
The sentences
Furthermore, an indirect treatment comparison between CBZ and vandetanib showed a positive trend in favour of CBZ in terms of PFS [ 24 ].
performed a prospective analysis as part of a multicenter International Thyroid Oncology Group phase II study of CBZ in patients with RAIR-DTC with bone metastases who progressed on prior VEGFR ‐targeted therapy: CBZ was associated with a highly significant reduction in all bone turnover markers (even when they were within normal limits at baseline) and a minor decreases in bone lesion uptake was noted on Sodium Fluoride PET in four out of six patients [ 37 ].